{"id":6391,"date":"2025-08-27T23:03:13","date_gmt":"2025-08-27T23:03:13","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/08\/27\/biotech-news-akeso-summit-keytruda-third-rock-harvard\/"},"modified":"2025-08-27T23:03:13","modified_gmt":"2025-08-27T23:03:13","slug":"biotech-news-akeso-summit-keytruda-third-rock-harvard","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/08\/27\/biotech-news-akeso-summit-keytruda-third-rock-harvard\/","title":{"rendered":"STAT+: Third Rock tops STAT\u2019s annual VC ranking"},"content":{"rendered":"<p>    STAT+: Third Rock tops STAT\u2019s annual VC ranking<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>Good morning. My colleague Allison DeAngelis has been working for months on our annual VC rankings report. Read on for what she found.<\/p>\n<h2 class=\"wp-block-heading\" id=\"h-third-rock-tops-stat-s-annual-vc-ranking\">Third Rock tops STAT\u2019s annual VC ranking<\/h2>\n<p>Among biotech venture capital firms, Third Rock Venture has generated the best returns on its investments in 2024 and 2025, according to STAT\u2019s annual VC rankings report.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/08\/27\/biotech-news-akeso-summit-keytruda-third-rock-harvard\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Elaine Chen<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/08\/27\/biotech-news-akeso-summit-keytruda-third-rock-harvard\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Third Rock tops STAT\u2019s annual VC ranking Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter in your inbox. Good morning. My colleague Allison DeAngelis has been working for months on our annual VC rankings report. Read on for what she found. Third Rock tops [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,58,2208,2209,2176,858,2207],"tags":[2150],"class_list":["post-6391","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-business","category-drug-development","category-drug-prices","category-pharma","category-research","category-the-readout","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6391"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=6391"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6391\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=6391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=6391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=6391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}